Trial reportTargeted oncology2014
Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial.
Trial report in Targeted oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I/II Study of Stereotactic Radiation Therapy and Concurrent and Adjuvant Sutent (SU11248) as Treatment for Oligometastatic Disease
Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing to Improve Outcomes for Patients With Limited Metastatic Disease That Failed First-Line Systemic Therapy
Who cites it
33 citing papers in PubMed.
- Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Trial
- A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.British journal of cancer · 2014Trial
- Lymphocyte Kinetics and Outcomes After Comprehensive Involved-Site Radiotherapy for Oligometastases.Cancers · 2026Article
- Long-term survival and undetectable circulating tumor DNA following comprehensive involved site radiotherapy for oligometastases.Scientific reports · 2025Article
- Article
- Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023Article
- Integrating stereotactic radiotherapy and systemic therapies.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022Review
- Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy (SBRT) for Oligometastases of Prostate Cancer in China.Frontiers in oncology · 2022Article
- Association of radiation dose intensity with overall survival in patients with distant metastases.Cancer medicine · 2021Article
- Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents.Translational lung cancer research · 2021Review
- Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation.The Journal of experimental medicine · 2021Article
- The promising role of radiotherapy in the treatment of advanced or metastatic renal cell carcinoma: a narrative review.Translational andrology and urology · 2020Review
- The emerging role of myeloid-derived suppressor cells in radiotherapy.Radiation oncology journal · 2020Article
- Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors.American journal of clinical oncology · 2020Article
- Oligometastatic Disease Management: Finding the Sweet Spot.Frontiers in oncology · 2020Review
- Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists.Journal of Cancer · 2020Review
- Role of stereotactic body radiation therapy for the management of renal cell carcinoma: tailoring treatment in the era of the "embarrassment of riches".Annals of translational medicine · 2019Article
- The NEAT Predictive Model for Survival in Patients with Advanced Cancer.Cancer research and treatment · 2018Article
- Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Preliminary results demonstrated that concurrent sunitinib and stereotactic body radiation therapy (SBRT) is an active regimen for metastases limited in number and extent. This analysis was conducted to determine the long-term survival and cancer control outcomes for this novel regimen. Forty-six patients with oligometastases, defined as five or fewer clinical detectable metastases from any primary site, were treated on a phase I/II trial from February 2007 to September 2010. The majority of patients were treated with 37.5 mg sunitinib (days 1-28) and SBRT 50 Gy (days 8-12 and 15-19) and maintenance sunitinib was used in 39 % of patients. Median follow up for surviving patients is 3.6 years. The 4-year estimates for local control, distant control, progression-free and overall survival were 75 %, 40 %, 34 % and 29 %, respectively. At last follow-up, 26 % of patients were alive without evidence of disease, 7 % were alive with distant metastases, 48 % died from distant metastases, 2 % died from local progression, 13 % died from comorbid illness, and 4 % died from treatment-related toxicities. Patients with kidney and prostate primary tumors were associated with a significantly improved overall survival (hazard ratio = 0.25, p = 0.04). Concurrent sunitinib and SBRT is a promising approach for the treatment of oligometastases and further study of this novel combination is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.